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A case of advanced rectal cancer treated by aggressive local and systemic treatment who has survived 
more than 7 years from initial recurrence is presented.  A 55-year-old woman was diagnosed with 
advanced lower rectal cancer and underwent a low anterior resection with complete removal of all 
regional lymph nodes and total mesorectal excision.  The tumor was diagnosed as a moderately dif-
ferentiated adenocarcinoma,  pStage IIIB (T3,  N2a,  M0).  Twenty-six months after the initial surgery,  
local recurrence in the pelvis was detected by computed tomography,  and total pelvic exenteration 
with distal sacrectomy (TPES) was performed after systemic chemotherapy with a molecular-targeted 
drug.  Six months after the TPES,  multiple lung metastases were detected.  Consequently,  the patient 
underwent radiofrequency ablation (RFA) and chemotherapy.  The disease has since been controlled 
for 38 months.  As volume control is essential for cancer treatment,  it may be important to combine 
appropriate local therapy with systemic therapy to metastatic or recurrent sites in order to achieve 
much longer disease control.
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olorectal cancer (CRC) is one of the leading 
causes of cancer-related death worldwide [1,  
2].  Some CRCs develop recurrence after curative 
resection,  but resection of recurrent sites sometimes 
contributes to longer survival [3-8].  On the other 
hand,  many cases develop repeat recurrence after 
re-operation.  In the past 10 years,  molecular-targeted 
drugs and new anticancer regimens such as oxaliplatin/ 
5FU/LV (FOLFOX) and irinotecan/5FU/LV 
(FOLFIRI) have enabled patients with metastatic or 
recurrent CRCs to have long survival periods,  with 
median overall survival of more than 20 months 
[9-12],  whereas systemic chemotherapy alone pro-
vides limited improvements in survival.  It seems 
important to give appropriate local treatments,  in 
addition to systemic therapy,  to patients with meta-
static or recurrent CRCs.  This manuscript reports a 
patient with recurrent rectal cancer who underwent 
systemic chemotherapy and aggressive local treatment,  
including total pelvic exenteration with distal sacrec-
tomy (TPES) to local recurrence in the pelvis and 
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radiofrequency ablation (RFA) to lung recurrence,  
who has survived for 7 years after the ﬁrst recur-
rence.
Case Report
　 A 55-year-old woman visited a previous hospital in 
2004 with a complaint of bloody stool.  The results of 
a subsequent colonoscopy and a barium enema study 
led to a diagnosis of lower rectal cancer.  She was thus 
referred to Okayama University Hospital for the 
management of her rectal cancer.  A computed tomog-
raphy (CT) scan and the colonoscopy showed a tumor 
measuring 35mm at the lower rectum,  regional lymph 
node swelling,  and no distant metastases.  Based on a 
diagnosis of locoregionally advanced lower rectal 
cancer,  a low anterior resection with complete removal 
of all regional lymph nodes and total mesorectal exci-
sion (TME) was performed.  Histopathologically,  the 
surgical margin was negative for cancer.  Based on the 
classiﬁcation of the seventh edition of the International 
Union against Cancer [13],  the tumor was diagnosed 
as a moderately diﬀerentiated adenocarcinoma,  pStage 
IIIB (T3,  N2a,  M0).  Genetic analysis performed with 
a direct sequencing method showed wild-type KRAS 
and BRAF oncogenes with stable microsatellite status.  
Postoperatively,  the patient developed major leakage,  
which led to rectovesical and rectovaginal ﬁstulas,  and 
consequently a diverting ileostomy was created.
　 In 2007,  26 months after the initial surgery,  a CT 
scan detected local recurrence in the pelvis.  Magnetic 
resonance imaging showed a recurrent tumor at the 
pelvic surface of the sacrum (Fig.  1).  She had under-
gone 11 courses of FOLFIRI (irinotecan 150mg/m2,  
l-leucovorin 200mg/m2,  and 5-ﬂuorouracil 400mg/m2 
bolus plus infusion of 2,400mg/m2/46h of a 2-week 
cycle) for 6 months,  and the tumor response at 3 
months was stable disease (SD),  but at 6 months it was 
progressive disease (PD),  according to the RECIST 
guideline criteria [14].  Therefore,  her chemotherapy 
regimen was changed to mFOLFOX6 with bevaci-
zumab (oxaliplatin 80mg/m2,  l-leucovorin 200mg/m2,  
5-ﬂuorouracil 400mg/m2 bolus plus infusion of 
2,400mg/m2/46h and bevacizumab 5mg/kg of a 
2-week cycle),  and the tumor response remained in SD 
status throughout 41 courses of the regimen.  In 2010,  
while the patient was undergoing chemotherapy,  
TPES was performed for the local recurrence since 
new recurrent lesions had not appeared.  Histopathol-
ogically,  the tumor was diagnosed as a moderately 
diﬀerentiated adenocarcinoma,  indicating metastasis 
from the rectal cancer,  and the surgical margin was 
negative.  After this very invasive surgery,  she was 
discharged without serious postoperative complica-
tions and received a careful follow-up examination.  
Six months after the TPES,  multiple lung metastases 
involving both lungs were detected by a thoracic CT 
scan.  Among the metastatic lesions,  there were 2 
tumors,  each measuring about 30mm in diameter,  at 
a right lower lobe of one of her lungs.  The tumors were 
treated with 48 Gy of stereotaxic radiation therapy 
(SRT),  and shrank after that.  At almost the same 
time as the SRT,  XELOX (oxaliplatin 130mg/m2 and 
capecitabine 1,000mg/m2 twice daily on days 1 to 15 
of a 3-week cycle) was started,  but the regimen was 
changed to irinotecan with cetuximab (irinotecan 
150mg/m2 and cetuximab 250mg/m2 on days 1 and 8 
of a 2-week cycle) due to oxaliplatin allergy at the 
third course.  After 10 courses of irinotecan with 
cetuximab,  only one of the metastatic lesions had 
grown.  CT-guided percutaneous RFA was performed 
for the tumor that had grown (Fig.  2).  The regimen 
was restarted after the RFA,  but the remaining lung 
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Fig. 1　 Magnetic resonance imaging shows a local recurrent 
tumor invading the surface of the sacrum (arrow).
metastatic tumors slowly grew during the following 8 
courses of irinotecan with cetuximab,  so her regimen 
was changed to XELIRI with bevacizumab (irrinote-
can 150mg/m2,  capecitabine 1,000mg/m2 twice daily 
on days 1 to 8 and bevacizumab 10mg/kg of a 2-week 
cycle).  Immediately after XELIRI with bevacizumab 
was started,  all remaining lung metastatic tumors 
showed cavitary change with size regression (Fig.  3).  
At the time of writing,  7 years after initial recur-
rence,  the patient have undergone the regimen,  and 
was doing well without new metastases.  Her clinical 
course is shown as Fig.  4.
Discussion
　 Patients with CRC can expect a long survival 
period if they undergo curative resection,  but those 
with regional lymph node metastases recur with a 
relatively high probability [2].  Local recurrence in 
the pelvis remains common after excision of rectal 
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Fig. 2　 Chest computed tomography scan shows a lung recurrent tumor treated with radiofre-
quency ablation (RFA) (A,  before RFA; B,  during RFA; C,  1 month after RFA).
A B
Fig. 3　 Chest computed tomography scan shows a lung recurrent tumor treated with XELIRI 
(capecitabine and irinotecan) with bevacizumab (A,  before treatment; B,  after treatment).
cancers,  although this is decreasing due to the use of 
TME [15].  Recurrent tumors in the pelvis often 
invade neighboring organs,  including the bladder,  
prostate,  uterus,  vagina,  pelvic wall,  and sacrum,  
and excision of such neighboring organs to achieve 
satisfactory histologically negative surgical margins is 
complicated.  TPES is a very invasive procedure and 
often causes complications such as urinary tract infec-
tion and pelvic sepsis [7,  8].  Quality of life in 
patients with TPES may decrease due to double 
ostomies (colostomy and urostomy); therefore,  it is 
necessary to choose surgery carefully.  However,  
there are no other therapies,  including chemotherapy 
and radiotherapy,  for locally recurrent CRCs that are 
equal in eﬀectiveness to surgical excision [7,  8].  A 
previous study of 44 cases treated by TPE for local 
recurrent CRCs found that the 5-year overall survival 
rate was 34ｵ and that independent factors for good 
prognoses were a negative resection margin,  a long-
term local disease-free interval (＞12 months),  and an 
absence of pain radiating to the buttock or further 
[16].  We should not hesitate to perform surgical 
excision for patients with local recurrence if there is 
a possibility of histologically negative surgical mar-
gins.
　 Lung recurrence is also a common recurrence pat-
tern for rectal cancers,  and surgical excision is now 
standard therapy for resectable lung recurrence sites,  
with 5-year overall survival of almost 30-45ｵ [5,  
6].  Since lung metastases often recur after surgical 
resection,  and because thoracic surgery decreases a 
patientʼs physical status,  including respiratory func-
tion,  there is a limit to curing by resection alone.  Our 
institution has performed CT-guided percutaneous 
RFA for lung tumors,  including early primary lung 
cancer and metastatic lung cancer,  since 2001.  The 
complications of RFA have mainly been pneumothorax 
and pleural eﬀusion; most occurrences of these are 
mild and do not require a chest tube.  Regarding mid-
term outcomes,  the 3-year overall survival rate is 
approximately 50ｵ [17].  We are planning a prospec-
tive clinical trial for RFA toward metastatic lung 
tumors of CRCs.  Considering repeatability,  the 
preservation of respiratory function,  and minimal 
invasiveness,  RFA can be an eﬀective treatment for 
lung recurrence of CRCs.
　 Since they appeared in the early 2000s,  new anti-
cancer regimens such as FOLFOX and FOLFIRI 
have prolonged the survival of patients with metastatic 
and recurrent CRC,  and molecular-targeted drugs 
have led to long survival [9-12].  However,  treatment 
by systemic chemotherapy alone has limited potential 
to prolong survival to,  for example,  more than 5 
years.  Although these new anticancer regimens are 
eﬀective,  cancer-free status as a result of surgical 
treatment seems to be elusive.  Table 1 shows cases in 
our department with recurrent CRCs that were 
treated with curative local treatment at least twice in 
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Fig. 4　 The clinical course and changes in the serum CEA level of this case are as above.
addition to systemic chemotherapy between 2004 and 
2011.  In our department,  6 cases,  including this case 
(case 6),  underwent curative local treatment for 
recurrent sites of CRCs at least twice,  and all 6 cases 
appeared to achieve relatively long disease control.  It 
is important to conduct appropriate local treatments at 
appropriate timing,  in addition to systemic therapy,  
as volume control is essential for cancer treatment.
　 In this case,  mutations of KRAS and BRAF onco-
genes and microsatellite status were analyzed,  and no 
mutation was found in the primary tumor.  KRAS 
mutation is widely known to be a negative predictive 
factor of anti-EGFR antibody [18].  It was recently 
reported that CRCs with nonmicrosatellite instability 
＋ BRAF mutation had a poor prognosis [19].  Such 
analyses of the mutation spectrum will be further used 
as prognostic and predictive factors for CRCs in the 
future.
　 In conclusion,  aggressive multimodality therapy,  
including not only systemic but also appropriate local 
therapy,  is important for patients with repeatedly 
recurrent CRCs to achieve long survival.
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Table 1　 Characteristics of cases with recurrent CRCs and undergoing curative local treatment twice or more
Case Gender
Primary tumor 1st recurrence
2nd
recurrence
3rd
recurrence
4th
recurrence
Outcome
Location Stage Histology
MS
status
KRAS/BRAF
status
Age
Duration from
initial surgery
Site
treatment
Site
treatment
Site
treatment
Site
treatment
Status
Duration from
1st recurrence
1 Female Colon IIIB Mod. non-MSI
BRAF
mutation
55 37 months
Uterus, LN
Resection
Lung
Resection
Local
non-ILT
dead 57 months
2 Male Rectum IIIC Muc. non-MSI
KRAS
mutation
74 12 months
Local
Resection
Lung
Resection
Local
non-ILT
alive 28 months
3 Male Colon IIA Mod. non-MSI
KRAS
mutation
57 17 months
Peritoneum
Resection
Liver
RFA
Peritoneum
Resection
alive 27 months
4 Male Rectum IIIB Mod. non-MSI
KRAS
mutation
53 16 months
Lung
Resection
Lung
RFA
LN
Resection
Lung
RFA
alive 83 months
5 Female Rectum IIIB Mod. non-MSI
Both
Wild type
65 5 months
Lung
Resection
Liver
Resection
Lung
non-ILT
alive 37 months
6 Female Rectum IIIB Mod. non-MSI
Both
Wild type
58 27 months
Local
Resection
Lung
RFA
Lung
non-ILT
alive 80 months
Mod./Muc,  moderately diﬀerentiated/mucinous adenocarcinoma; MS(I),  microsatellite (instability);  LN,  lymph node;  non-ILT,  non-
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